BR112017019071A2 - método para tratar colangite esclerosante primária - Google Patents

método para tratar colangite esclerosante primária

Info

Publication number
BR112017019071A2
BR112017019071A2 BR112017019071A BR112017019071A BR112017019071A2 BR 112017019071 A2 BR112017019071 A2 BR 112017019071A2 BR 112017019071 A BR112017019071 A BR 112017019071A BR 112017019071 A BR112017019071 A BR 112017019071A BR 112017019071 A2 BR112017019071 A2 BR 112017019071A2
Authority
BR
Brazil
Prior art keywords
sclerosing cholangitis
primary sclerosing
treat primary
subject
treat
Prior art date
Application number
BR112017019071A
Other languages
English (en)
Inventor
Abhyankar Brihad
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR112017019071A2 publication Critical patent/BR112017019071A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

é divulgado um método para tratar um indivíduo que tem colangite esclerosante primária compreendendo administrar ao referido indivíduo uma quantidade eficaz de um anticorpo humanizado ou fragmento de ligação a antígeno do mesmo tendo especificidade de ligação para integrina a4ß7.
BR112017019071A 2015-03-06 2016-03-04 método para tratar colangite esclerosante primária BR112017019071A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129698P 2015-03-06 2015-03-06
PCT/US2016/020819 WO2016144720A1 (en) 2015-03-06 2016-03-04 Method of treating primary sclerosing cholangitis

Publications (1)

Publication Number Publication Date
BR112017019071A2 true BR112017019071A2 (pt) 2018-04-17

Family

ID=55699788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019071A BR112017019071A2 (pt) 2015-03-06 2016-03-04 método para tratar colangite esclerosante primária

Country Status (11)

Country Link
US (2) US20180051086A1 (pt)
EP (2) EP3265492A1 (pt)
JP (1) JP6942053B2 (pt)
KR (1) KR20170120622A (pt)
AU (1) AU2016229193A1 (pt)
BR (1) BR112017019071A2 (pt)
CA (1) CA2978725A1 (pt)
EA (1) EA201791970A1 (pt)
MA (1) MA41636A (pt)
MX (1) MX2017011272A (pt)
WO (1) WO2016144720A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160700A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
CA3017743A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
EP3468597A1 (en) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
BR112021024897A2 (pt) * 2019-06-10 2022-01-18 Takeda Pharmaceuticals Co Métodos de produção de um anticorpo anti-a4ss7

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ATE424417T1 (de) * 1998-05-13 2009-03-15 Genentech Inc Diagnose und behandlung von hepatischen krankheiten
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
ATE517102T1 (de) 2002-11-18 2011-08-15 Chemocentryx Inc Arylsulfonamide
PT2322556E (pt) 2004-09-03 2016-02-15 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
MX338969B (es) 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7

Also Published As

Publication number Publication date
MX2017011272A (es) 2018-01-12
CA2978725A1 (en) 2016-09-15
EP4257200A2 (en) 2023-10-11
EP3265492A1 (en) 2018-01-10
JP2018508526A (ja) 2018-03-29
US20180051086A1 (en) 2018-02-22
EA201791970A1 (ru) 2018-07-31
EP4257200A3 (en) 2024-01-03
WO2016144720A1 (en) 2016-09-15
AU2016229193A1 (en) 2017-09-21
MA41636A (fr) 2018-01-09
US20210388092A1 (en) 2021-12-16
KR20170120622A (ko) 2017-10-31
JP6942053B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
PH12018502046A1 (en) Methods for inhibiting angiogenesis in a subject in need thereof
BR112017019071A2 (pt) método para tratar colangite esclerosante primária
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201892482A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
BR112017027990A2 (pt) modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
BR112017025693A2 (pt) anticorpos anti-cd40 e seus usos
PE20171067A1 (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2018009680A (es) Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3.
HK1255916A1 (zh) 組織蛋白去乙醯酶抑制劑與免疫檢查點抑制抗體的合併癌症治療
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
IL254529A0 (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
BR112017002433A2 (pt) anticorpos anticeramida
DOP2016000120A (es) Nuevos inhibidores de dgat2
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112016008082A2 (pt) métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]